Skye Bioscience Statistics
Total Valuation
Skye Bioscience has a market cap or net worth of $57.92 million. The enterprise value is -$10.04 million.
Important Dates
The last earnings date was Thursday, March 20, 2025, after market close.
Earnings Date | Mar 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Skye Bioscience has 30.97 million shares outstanding. The number of shares has increased by 420.79% in one year.
Current Share Class | 30.97M |
Shares Outstanding | 30.97M |
Shares Change (YoY) | +420.79% |
Shares Change (QoQ) | +2.96% |
Owned by Insiders (%) | 2.99% |
Owned by Institutions (%) | 41.84% |
Float | 15.69M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.85 |
P/TBV Ratio | 0.85 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.32, with a Debt / Equity ratio of 0.01.
Current Ratio | 16.32 |
Quick Ratio | 15.77 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -40.30 |
Financial Efficiency
Return on equity (ROE) is -80.48% and return on invested capital (ROIC) is -53.09%.
Return on Equity (ROE) | -80.48% |
Return on Assets (ROA) | -44.56% |
Return on Invested Capital (ROIC) | -53.09% |
Return on Capital Employed (ROCE) | -44.13% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.42M |
Employee Count | 11 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Skye Bioscience has paid $10,071 in taxes.
Income Tax | 10,071 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.96% in the last 52 weeks. The beta is 1.71, so Skye Bioscience's price volatility has been higher than the market average.
Beta (5Y) | 1.71 |
52-Week Price Change | -86.96% |
50-Day Moving Average | 2.73 |
200-Day Moving Average | 4.53 |
Relative Strength Index (RSI) | 34.83 |
Average Volume (20 Days) | 197,286 |
Short Selling Information
The latest short interest is 2.06 million, so 6.64% of the outstanding shares have been sold short.
Short Interest | 2.06M |
Short Previous Month | 2.17M |
Short % of Shares Out | 6.64% |
Short % of Float | 13.10% |
Short Ratio (days to cover) | 14.81 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -30.19M |
Pretax Income | -42.28M |
Net Income | -26.57M |
EBITDA | -29.90M |
EBIT | -30.19M |
Earnings Per Share (EPS) | -$0.73 |
Full Income Statement Balance Sheet
The company has $68.42 million in cash and $455,590 in debt, giving a net cash position of $67.96 million or $2.19 per share.
Cash & Cash Equivalents | 68.42M |
Total Debt | 455,590 |
Net Cash | 67.96M |
Net Cash Per Share | $2.19 |
Equity (Book Value) | 68.15M |
Book Value Per Share | 2.20 |
Working Capital | 66.49M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$25.24 million and capital expenditures -$1.60 million, giving a free cash flow of -$26.84 million.
Operating Cash Flow | -25.24M |
Capital Expenditures | -1.60M |
Free Cash Flow | -26.84M |
FCF Per Share | -$0.87 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Skye Bioscience does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -420.79% |
Shareholder Yield | n/a |
Earnings Yield | -45.87% |
FCF Yield | -46.34% |
Analyst Forecast
The average price target for Skye Bioscience is $18.00, which is 862.57% higher than the current price. The consensus rating is "Buy".
Price Target | $18.00 |
Price Target Difference | 862.57% |
Analyst Consensus | Buy |
Analyst Count | 7 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | 29.71% |
Stock Forecasts Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.004:1.
Last Split Date | Sep 8, 2023 |
Split Type | Reverse |
Split Ratio | 0.004:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |